Patent · US Active

Pteridine ketone derivative and applications thereof as EGFR, BLK, and FLT3 inhibitor

US9670213B2 · kind B2 · utility

1Cited by

0References

9Claims

0Family size

Assignee

East China University of Science and Technology · CN

Inventors

Honglin Li · Shanghai, CN
Yufang Xu · Shanghai, CN
Zhenjiang ZHAO · Zhuhai, CN
Xiaofeng Liu · Dallas, US
Wei Zhou · Scotch Plains, US
Fang Bai · Shanghai, CN
Mengzhu Xue · Shanghai, CN
Lei Zhang · Beijing, CN
Youli Zhang · Shanghai, CN

Key dates

Filing date	Apr 2, 2013
Grant date	Jun 6, 2017
Priority date	—
Expiry date	Apr 2, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D239/50
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are a pteridine ketone derivative used as an EGFR, BLK, and FLT3 inhibitor and applications thereof. Specifically, provided are a compound of the following formula I, a pharmaceutical composition containing the compound of the formula I, and use of compound in preparing medicine for treating diseases mediated by EGFR, BLK, or FLT3 or inhibiting EGFR, BLK, and FLT3.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.